These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15829493)

  • 1. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results.
    Mosolits S; Ullenhag G; Mellstedt H
    Ann Oncol; 2005 Jun; 16(6):847-62. PubMed ID: 15829493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
    Mosolits S; Nilsson B; Mellstedt H
    Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research.
    Bhargava A; Mishra D; Banerjee S; Mishra PK
    J Drug Target; 2013 Feb; 21(2):126-36. PubMed ID: 23061479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief K; Nijman HW
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007287. PubMed ID: 20091627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential role of tumor vaccines in GI malignancies.
    Laheru DA; Jaffee EM
    Oncology (Williston Park); 2000 Feb; 14(2):245-56; discussion 259-60, 265. PubMed ID: 10736811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for gastrointestinal malignancies.
    Toomey PG; Vohra NA; Ghansah T; Sarnaik AA; Pilon-Thomas SA
    Cancer Control; 2013 Jan; 20(1):32-42. PubMed ID: 23302905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
    Staib L; Birebent B; Somasundaram R; Purev E; Braumüller H; Leeser C; Küttner N; Li W; Zhu D; Diao J; Wunner W; Speicher D; Beger HG; Song H; Herlyn D
    Int J Cancer; 2001 Apr; 92(1):79-87. PubMed ID: 11279610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy.
    Elkord E; Hawkins RE; Stern PL
    Expert Opin Biol Ther; 2008 Apr; 8(4):385-95. PubMed ID: 18352844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
    Van Driessche A; Berneman ZN; Van Tendeloo VF
    Oncologist; 2012; 17(2):250-9. PubMed ID: 22291091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
    Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
    Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.
    Abdul-Latif M; Townsend K; Dearman C; Shiu KK; Khan K
    Cancer Treat Rev; 2020 Aug; 88():102030. PubMed ID: 32505807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.
    Iwasa S; Yamada Y; Heike Y; Shoji H; Honma Y; Komatsu N; Matsueda S; Yamada A; Morita M; Yamaguchi R; Tanaka N; Kawahara A; Kage M; Shichijo S; Sasada T; Itoh K
    Cancer Sci; 2016 May; 107(5):590-600. PubMed ID: 26920496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell vaccination of patients with metastatic colorectal cancer.
    Burgdorf SK
    Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
    Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
    Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccination for cancer immunotherapy: antigen selection and clinical responses.
    Geldmacher A; Freier A; Losch FO; Walden P
    Hum Vaccin; 2011; 7 Suppl():115-9. PubMed ID: 21245666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.